Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

Open-label, Single-arm, Multicenter, Long-term Study to Evaluate Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Pediatric Subjects With Epilepsy

This study will evaluate the safety and tolerability of brivaracetam in pediatric subjects with epilepsy.

Study Overview

• Status: Completed
• Conditions: Epilepsy
• Intervention / Treatment: Drug: Brivaracetam (BRV)

Detailed Description

This is a Phase 3, open-label, single-arm, multicenter, long-term study to evaluate the safety and efficacy of brivaracetam (BRV) in children with epilepsy.

This study was initially designed for pediatric subjects who had completed a previous BRV study.

With protocol amendment 4, enrollment for "directly enrolled" subjects was modified from 'up to' an additional 100 subjects to "at least" 100 subjects, keeping the planned total enrollment of approximately 600 subjects to allow flexibility in the number of patients reaching 1 year of exposure.

With protocol amendment 5, entry criteria for subjects coming for other pediatric core studies in development were included. Additional clarity was provided for subjects enrolled in N01266 that temporary roll over to one of those studies and resume participation in N01266.

With protocol amendment 6, central EEG reading and entry visit EEG were removed. Some clarifications on study assessments (questionnaires, EEGs) was provided and inclusion criteria were aligned from an earlier local amendment.

With protocol amendment 7, the pregnancy section was updated to clarify that Pregnancy Report and Outcome Form has to be completed in all pregnancies.

With protocol amendment 8, re-categorization of study variables in compliance with reporting registries was performed. Modifications due to COVID19 pandemic were implemented and clarification provided that participants may transition to another BRV study.

The primary objective is to evaluate the long-term safety and tolerability of BRV. The secondary objective is to assess the efficacy of BRV during long-term exposure.

• Study Type: Interventional
• Enrollment (Actual): 257
• Phase: Phase 3

Expanded Access

Available outside the clinical trial. See expanded access record.

Contacts and Locations

Study Locations

• Belgium
  • Brussels, Belgium
    • N01266 202
  • Brussels, Belgium
    • N01266 203
  • Leuven, Belgium
    • N01266 201
  • Leuven, Belgium
    • N01266 204
• Czechia
  • Hradec Králové, Czechia
    • N01266 502
  • Ostrava Prouba, Czechia
    • N01266 504
  • Prague, Czechia
    • N01266 240
• France
  • Lille, France
    • N01266 207
  • Paris, France
    • N01266 206
• Germany
  • Bayern, Germany
    • N01266 218
  • Freiburg im Breisgau, Germany
    • N01266 209
• Hungary
  • Budapest, Hungary
    • N01266 210
  • Budapest, Hungary
    • N01266 224
  • Budapest, Hungary
    • N01266 247
  • Debrecen, Hungary
    • N01266 222
  • Miskolc, Hungary
    • N01266 232
• Ireland
  • Cork, Ireland
    • N01266 211
• Italy
  • Messina, Italy
    • N01266 212
  • Parma, Italy
    • N01266 213
  • Pavia, Italy
    • N01266 238
  • Pavia, Italy
    • N01266 239
  • Roma, Italy
    • N01266 230
  • Roma, Italy
    • N01266 256
• Mexico
  • Aguascalientes, Mexico
    • N01266 223
  • Chihuahua City, Mexico
    • N01266 611
  • Culiacán, Mexico
    • N01266 609
  • Guadalajara, Mexico
    • N01266 603
  • Monterrey, Mexico
    • N01266 610
• Poland
  • Bialystok, Poland
    • N01266 404
  • Gdansk, Poland
    • N01266 403
  • Kielce, Poland
    • N01266 406
  • Krakow, Poland
    • N01266 402
  • Poznan, Poland
    • N01266 401
  • Szczecin, Poland
    • N01266 407
  • Wroclaw, Poland
    • N01266 405
• Spain
  • Barcelona, Spain
    • N01266 309
  • Madrid, Spain
    • N01266 306
  • Palma de Mallorca, Spain
    • N01266 301
  • Seville, Spain
    • N01266 248
  • Valencia, Spain
    • N01266 308
• United Kingdom
  • London, United Kingdom
    • N01266 215
• United States
  • California
    • Los Angeles, California, United States, 90027
      • N01266 243
  • Florida
    • Gulf Breeze, Florida, United States, 32561
      • N01266 108
    • Wellington, Florida, United States, 33470
      • N01266 103
  • Illinois
    • Chicago, Illinois, United States, 60611
      • N01266 118
  • Massachusetts
    • Boston, Massachusetts, United States, 02111
      • N01266 106
  • Minnesota
    • Saint Paul, Minnesota, United States, 55102
      • N01266 101
  • Missouri
    • Chesterfield, Missouri, United States, 63017
      • N01266 113
  • New York
    • Buffalo, New York, United States, 14222
      • N01266 105
    • New York, New York, United States, 10029
      • N01266 252
    • Rochester, New York, United States, 14642
      • N01266 104
  • North Carolina
    • Durham, North Carolina, United States, 27710
      • N01266 237
  • Ohio
    • Cincinnati, Ohio, United States, 45229
      • N01266 107
    • Columbus, Ohio, United States, 43205
      • N01266 111
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15201
      • N01266 114
  • Texas
    • Houston, Texas, United States, 77030
      • N01266 117

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 4 weeks to 17 years (Child)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

All Subjects:

• Informed Consent form (ICF) is signed and dated by the parent(s) or legal representative(s)
• Subject/legal representative is considered reliable and capable of adhering to the protocol
• For female subjects:
• Subject is not of childbearing potential

OR if women of childbearing potential, and sexually active only if:

• Adequate Contraceptive method
• Negative pregnancy test
• Understands the consequences and potential risks of inadequately protected sexual activity, understands and properly uses contraceptive methods, and is willing to inform the Investigator of any contraception changes

Long Term Follow-up Subjects:

- Male or female subjects having participated in a core study with a confirmed diagnosis of epilepsy and for whom a reasonable benefit from long-term administration of BRV is expected

Directly Enrolled Subjects:

• Subject is a male or female ≥4 years to <17 years of age
• Subject has a clinical diagnosis of partial-onset seizures (POS) according to the International League Against Epilepsy (ILAE) classification
• Subject has an EEG compatible with the clinical diagnosis of POS
• Subject has been observed to have uncontrolled POS after an adequate course of treatment (in the opinion of the Investigator) with at least 1 antiepileptic drug (AED; concurrently or sequentially)
• Subject had at least 1 seizure (POS) during the 3 weeks before the Screening Visit (ScrV)
• Subject is taking at least 1 AED. All AEDs need to be at a stable dose for at least 7 days before the ScrV. Vagal nerve stimulator stable for at least 2 weeks before the ScrV is allowed and will be counted as a concomitant AED. Benzodiazepines taken more than once a week (for any indication) will be considered as a concomitant AED

Exclusion Criteria:

All Subjects:

• Subject is a pregnant or nursing female
• Subject has severe medical, neurological, or psychiatric disorders or laboratory values, which may have an impact on the safety of the subject.
• Subject has planned participation in any clinical study of another investigational drug or device.
• Subject has >1.5x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >1.0xULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert's syndrome). If subject has elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin <35%). N01349 subjects with a total bilirubin > ULN may be considered for the study if benign unconjugated hyperbilirubinemia is suspected in the context of prolonged neonatal jaundice, after discussion with the medical monitor. For randomized subjects with a baseline result >ULN for ALT, AST, ALP, or total bilirubin, a baseline diagnosis and/or the cause of any clinically meaningful elevation must be understood and recorded in the eCRF. If subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at the baseline referenced in Table 5-1 for LTFU subjects and at the Screening Visit for directly enrolled subjects, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject must be discussed with the Medical Monitor. Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated once for confirmation. This includes re-screening.
• Subject has chronic liver disease.

Long Term Follow-up Subjects:

• Subject had hypersensitivity to BRV or excipients or comparative drugs as stated in this protocol during the course of the core study.
• Subject had poor compliance with the visit schedule or medication intake in the core study.
• Subject ≥6 years of age has a lifetime history of suicide attempt (including actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at the EV. If a subject has active suicidal ideation without a specific plan as indicated by a positive response ("Yes") to Question 4 of Columbia-Suicide Severity Rating Scale (C SSRS) at the EV, the subject should be referred immediately to a Mental Healthcare Professional and may be excluded from the study based upon the Investigator's judgment of benefit/risk of continuing the subject in the study/on study medication.

Directly Enrolled Subjects:

• Subject has previously received BRV.
• Subject had concomitant use of LEV at the ScrV. In addition, the use of LEV is prohibited for at least 4 weeks prior to the ScrV.
• Subject has epilepsy secondary to a progressive cerebral disease or tumor, or any other progressively neurodegenerative disease. Stable arteriovenous malformations, meningiomas or other benign tumors may be acceptable according to Investigator's opinion.
• Subject has a history of primary generalized epilepsy.
• Subject has a history of status epilepticus in the month immediately prior to the ScrV or during the Up Titration Period.
• Subject has a history or presence of pseudoseizures.
• Subject is suffering only from febrile seizures.
• Subject is on felbamate with less than 18 months continuous exposure. Subject who has taken felbamate for a combined duration of treatment and wash out of <18 months before the ScrV.
• Subjects treated with vigabatrin who have visual field defects.
• Subject has an allergy to pyrrolidone derivatives or investigational product excipients or a history of multiple drug allergies.
• Subject has any clinically significant acute or chronic illness as determined during the physical examination or from other information available to the Investigator (eg, bone marrow depression, chronic hepatic disease, severe renal impairment, psychiatric disorder).
• Subject has an underlying disease or is receiving a treatment that may interfere with the absorption, distribution, metabolism, and elimination of the study drug.
• Subject has any medical condition that might interfere with his/her study participation (eg, serious infection or scheduled elective surgery).
• Subject has a terminal illness.
• Subject has any clinically significant deviations from reference range values for laboratory parameters as determined by the Investigator.
• Subject has a clinically relevant ECG abnormality according to the Investigator.
• Subject had major surgery within 6 months prior to the ScrV.
• Subject received any investigational drug or device within the 30 days prior to the ScrV.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Brivaracetam

Drug: Brivaracetam (BRV); The max BRV dose will be 5.0 mg/kg/day, not to exceed a dose of 200 mg/day for subjects with body weight >40kg. Subjects may receive oral solution or oral tablets. The LTFU subjects will start dosing in N01266 on the individualized BRV dose they were receiving at the completion of the core study. Subjects must be able to tolerate the min BRV dose specified in the core study to be eligible for entry into the Evaluation Period of N01266. Dose can be adjusted as considered necessary by the Investigator and required by the subject's medical condition. All subjects who prematurely discontinue the study should complete an EDV and have their BRV dose down titrated by a maximum of half the dose every week for a maximum of 4 weeks until a dose of 1 mg/kg/day (50 mg/day for subjects with body weights >50kg) is reached.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study	TEAEs are defined as AEs that had onset on or after the day of first BRV dose.	From Baseline to end of study (up to 10 years)
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study	TEAEs are defined as AEs that had onset on or after the day of first BRV dose. A SAE was defined as an event that met 1 or more of the below criteria: a) Death, b) Life-threatening, (Life-threatening did not include a reaction that might have caused death had it occurred in a more severe form.) c) Significant or persistent disability/incapacity, d) Congenital anomaly/birth defect (including that occurring in a fetus), e) Important medical event that, based upon appropriate medical judgment, may have jeopardized participant and may have required medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious, (Important medical events may have included allergic bronchospasm requiring intensive treatment in an emergency room [ER] or at home) f) Initial inpatient hospitalization or prolongation of hospitalization. (A participant admitted to a hospital, even if released on the same day, met the criteria for the initial inpatient hospitalization).	From Baseline to end of study (up to 10 years)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Absolute Change in 28-days Adjusted Partial-onset-seizure (POS) Frequency for Participants Aged ≥2 Years From Baseline to the End of the Evaluation Period in Participants With POS Only (Based on Daily Record Card [DRC])	Absolute change in seizure frequency per 28 days based on the daily record card (DRC) data, is calculated as baseline seizure frequency per 28 days minus post-Baseline seizure frequency per 28 days. The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28. This OM was analyzed in participants ≥2 years (per DRC data) only. Here in the study FAS indicates Full Analysis Set, EEG indicates electroencephalogram, OM indicates Outcome measure	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422]; and DE participants: Baseline of current study) to the end of the evaluation period (up to 10 years)
Percent Change in 28-days Adjusted Partial-onset-seizure (POS) Frequency for Participants Aged ≥2 Years From Baseline to the End of the Evaluation Period in Participants With POS Only (Based on DRC Data)	Percent change is calculated as absolute change in seizure frequency per 28 days divided by baseline seizure frequency per 28 Days multiplied to 100. The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28. This OM was analyzed in participants ≥2 years (per DRC data) only.	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422]; and DE participants: Baseline of current study) to the end of the evaluation period (up to 10 years)
50% Responder Rate for Participants ≥2 Years of Age for Total Seizures (All Types) (Based on DRC Data)	A responder is defined as a participant with a ≥50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants or during this study for DE participants. This OM was analyzed in participants ≥2 years (per DRC data) only.	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422]; and DE participants: Baseline of current study) to the end of the evaluation period (up to 10 years)
Absolute Change in Average Daily Frequency (ADF) of Partial-onset-seizures (POS) in Participants <2 Years of Age With POS Only (Based on EEG Data)	Absolute change in ADF is calculated as the baseline ADF minus post-baseline ADF. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24. This OM was analyzed in participants <2 years (per EEG data) only.	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
Percent Change in Average Daily Frequency (ADF) of Partial-onset-seizures (POS) in Participants <2 Years of Age With POS Only (Based on EEG Data)	Percent change in average daily frequency (ADF) is calculated as absolute change in ADF divided by baseline ADF multiplied to 100. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24. This OM was analyzed in participants <2 years (per EEG data) only.	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
50% Responder Rate for Participants <2 Years of Age for Total Seizures (All Types) (Based on EEG Data)	A responder is defined as a participant with a ≥50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants. This OM was analyzed in participants <2 years (per EEG data) only.	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
Absolute Change in Average Daily Frequency of POS in Participants <2 Years of Age With Typical Absence Seizures (Based on EEG Data)	Absolute change in ADF is calculated as the baseline ADF minus post-baseline ADF. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24.	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
Percent Change in Average Daily Frequency of POS in Participants <2 Years of Age With Typical Absence Seizures (Based on EEG Data)	Percent change in average daily frequency (ADF) is calculated as absolute change in ADF divided by baseline ADF multiplied to 100. ADF is calculated as (number of seizures from central reader divided by stop date and time of EEG minus start date and time of EEG) multiplied to 60, multiplied to 24.	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)
50% Responder Rate for Total Seizures (All Types) in Participants <2 Years of Age With Typical Absence Seizures (Based on EEG Data)	A responder is defined as a participant with a ≥50% reduction in seizure frequency from the baseline period of the previous study for LTFU participants.	From Baseline (LTFU participants: Baseline of previous studies N01263 [NCT00422422] or N01349 [NCT03325439]) to the end of the evaluation period (up to 10 years)

Collaborators and Investigators

• Sponsor: UCB Pharma SA
• Investigators: Study Director: UCB Cares, +1 877 822 9493 (UCB)

Publications and helpful links

General Publications

• Markham A. Brivaracetam: First Global Approval. Drugs. 2016 Mar;76(4):517-22. doi: 10.1007/s40265-016-0555-6.
• Lagae L, Klotz KA, Fogarasi A, Floricel F, Reichel C, Elshoff JP, Fleyshman S, Kang H. Long-term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open-label, follow-up trial. Epilepsia. 2023 Nov;64(11):2934-2946. doi: 10.1111/epi.17754. Epub 2023 Sep 5.
• Bourikas D, Elmoufti S, Elshoff JP, Little A, Pucylowski K, Moseley B, Lagae L. Long-term tolerability and efficacy of adjunctive brivaracetam in pediatric patients with generalized-onset seizures: Subgroup analysis of an open-label, follow-up trial. Epilepsy Behav. 2025 Oct;171:110569. doi: 10.1016/j.yebeh.2025.110569. Epub 2025 Jul 29.

Helpful Links

• FDA Safety Alerts and Recalls
• Product Information

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2011
• Primary Completion (Actual): February 3, 2022
• Study Completion (Actual): February 3, 2022

Study Registration Dates

• First Submitted: May 31, 2011
• First Submitted That Met QC Criteria: May 31, 2011
• First Posted (Estimated): June 2, 2011

Study Record Updates

• Last Update Posted (Actual): October 20, 2025
• Last Update Submitted That Met QC Criteria: October 1, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Keywords: Adolescents; Epilepsy; Child; Infant; Brivaracetam; Partial onset seizures
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Epilepsy; Anticonvulsants; brivaracetam
• Other Study ID Numbers: N01266; 2011-000374-60 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No